(Q24239993)

1

0 references

Kirubah V David

2

0 references

Sushil M John

3

0 references

Venkatesan Sankarapandian

Cochrane Database of Systematic Reviews

4

0 references

publication date

7 October 2009

0 references

published in

0 references

cites work

Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

[Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Sulfamethoxazole- trimethoprim versus ampicillin in treatment of acute invasive diarrhea in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Furazolidone versus ampicillin in the treatment of traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Bicozamycin, A Poorly Absorbable Antibiotic, Effectively Treats Travelers' Diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Optimal dosing of trimethoprim-sulfamethoxazole when used with loperamide to treat traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Randomized trial of high- and low-dose ampicillin therapy for treatment of severe dysentery due to Shigella dysenteriae type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Single-dose ampicillin therapy for severe shigellosis in Bangladesh.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Comparative efficacies of pivmecillinam and ampicillin in acute shigellosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Comparative Efficacy of Cephalexin and Ampicillin for Shigellosis and Other Types of Acute Diarrhea in Infants and Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Treatment of traveler's diarrhea with ciprofloxacin and loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

[Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Vitamin A for treating shigellosis. Study did not prove benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Multidrug-resistant Shigella dysenteriae type 1: forerunners of a new epidemic strain in eastern India?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

Perinatal outcome following third-trimester exposure to paroxetine: an alternative interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Clinical and Bacteriological Evaluation of Antibiotic Treatment in Shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Adverse Effect of Lomotil Therapy in Shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Shigellemia in AIDS patients: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Ciprofloxacin in the treatment of acute bacterial diarrhea: a double blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Antimicrobial resistance trends in Shigella serogroups isolated in Israel, 1990-1995.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Treatment of severe bacillary dysentery with trimethoprim alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Lomefloxacin versus trimethoprim/sulfamethoxazole in the treatment of adults with acute bacterial diarrhea.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis. A double-blind study with ampicillin and neomycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparison of intramuscular and oral ampicillin therapy for shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Optimal dosage of ampicillin for shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparison of trimethoprim-sulfamethoxazole and ampicillin theraphy for shigellosis in ambulatory

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing frequency of multiple resistance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Shifting serotypes, plasmid profile analysis and antimicrobial resistance pattern of shigellae strains isolated from Kolkata, India during 1995-2000.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Trends in population-based active surveillance for shigellosis and demographic variability in FoodNet sites, 1996-1999.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Laboratory-confirmed shigellosis in the United States, 1989-2002: epidemiologic trends and patterns

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Antimicrobial therapy for travelers' diarrhea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Double-blind comparison of oral gentamicin and nalidixic acid in the treatment of acute shigellosis in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Antibiotic Treatment of Acute Shigellosis: Failure of Cefamandole Compared with Trimethoprim/Sulfamethoxazole and Ampicillin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Treatment of shigellosis with cefixime: two days vs. five days

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparative efficacy of cefixime and ampicillin-sulbactam in shigellosis in children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

[Effects of lividomycin on bacillary dysentery and related disorders. Comparison with the effects of kanamycin by a double blind method]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

[Comparison of clinical efficacy of fosfomycin (FOM) and kanamycin (KM) in bacillary dysentery by double blind method (author's transl)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

[Comparison of clinical efficacy of pipemidic acid (PPA) and kanamycin (KM) in bacillary dysentery by double blind method]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

[Comparison of clinical efficacy of ofloxacin COFLX: DL-8280) and pipemidic acid (PPA) in acute infectious diarrhea by a double-blind method. The Japan Research Committee of Ofloxacin, Research Group for Acute Infectious Diarrhea]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

[Comparison of clinical efficacy of norfloxacin (NFLX) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Norfloxacin Research Group Enteritis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

[Comparison of clinical efficacy of ciprofloxacin (CPFX, BAY o 9867) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Ciprofloxacin, Research Group for Infectious Enteritis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Clinical Evaluation of Co-trimoxazole and Furazolidone in Treatment of Shigellosis in Children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Antimicrobial Therapy of Bacterial Diarrhea in Adult Residents of Mexico – Lack of an Effect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Bioactive polymers: in vitro and in vivo study of controlled release neomycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Epidemiology of highly endemic multiply antibiotic-resistant shigellosis in children in the Peruvian Amazon.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

A randomized, controlled, single-blind study comparing furazolidone with trimethoprim-sulfamethoxazole in the empirical treatment of acute invasive diarrhea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparison of pivmecillinam and nalidixic acid in the treatment of acute shigellosis in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

A Comparison of the Combination Pivmecillinam/Pivampicillin and Co-trimoxazole in the Treatment of Convalescent Carriers of Salmonella and Shigella

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Comparative efficacy of pivmecillinam and cotrimoxazole in acute shigellosis in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

HIV infection as a risk factor for shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Treatment of Acute Nonspecific Gastroenteritis of Infants and Young Children with Erythromycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Empirical treatment of Shigella dysentery with trimethoprim: five-day course vs. single dose

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Randomized Clinical Trial of Norfloxacin for Shigellosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Short-course norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021

Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006784.PUB2

7 January 2021